BiotechTube
Home/Pipeline/PBI-04711

PBI-04711

Not Specified

Pre-clinicalActive

Key Facts

Indication
Not Specified
Phase
Pre-clinical
Status
Active
Company
Phoenix Biotechnology

About Phoenix Biotechnology

Phoenix Biotechnology is a private, clinical-stage company leveraging the bioactive compounds of the Nerium oleander plant to develop novel therapeutics for oncology, virology, and neurodegeneration. Its lead candidate, PBI-05204, has progressed to Phase II trials for glioblastoma and other cancers, demonstrating a unique mechanism of action involving FGF-2 inhibition and immune modulation. The company's strategy targets high-unmet-need indications with a natural product-derived platform, aiming for safer, more affordable treatments, though it faces challenges typical of botanical drug development and early-stage biotechs.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesNeurodegenerative DiseasesInflammatory Diseases

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved